Targeted next generation sequencing panel revealed a TERT promoter mutation (VAF 55%) identical to the peri-rolandic lesion and an IDH1 R132G mutation (VAF 46%) not seen in the patient’s supratentorial tumor. Here, IDH1 is linked to neoplasm.